Novo and Lilly compete in India as obesity drugs demand hikes
Demand for weight-loss drugs in India has shot up.
And rivals Novo Nordisk and Eli Lilly are battling for market share.
That's according to research firm Pharmarack.
It said sales of Lilly's Mounjaro, which launched in March, doubled from May to June.
Overall, it's almost hit close to 88,000 units sold - over $3 million.
:: Novo Nordisk
Meanwhile, Pharmarack said Novo sold almost 1,800 units of Wegovy since its late-June launch.
Medical journal the Lancet has said the incidence of obesity and diabetes is rising in India.
And the country ranks among the worst three globally for high obesity rates.
Pharmarack said the Indian obesity market has grown fivefold since 2021 and is valued at $73 million.
And affordability and willingness to try new drugs for obesity have propelled the growth of the market.
While Wegovy's only just launched, the active ingredient in it - semaglutide - has a two-thirds share in the Indian market, according to Pharmarack.
And Novo has sold oral versions of semaglutide for diabetes in India since 2022.
However, semaglutide will lose patent protection in India next year.
Enabling generic drugmakers to produce cheaper versions of Wegovy as India becomes a key battleground for drugmakers in the global obesity market.
Error al recuperar los datos
Inicia sesión para acceder a tu cartera de valores
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Market to Reach $14.34 Billion by 2034, Driven by Innovative R&D, Strategic Collaborations, and Drug Formulation Advancements
The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by rising diabetes and obesity rates, innovative drug formulations, and supportive healthcare policies, the market is expanding. Key players include Eli Lilly, Sanofi, and Novo Nordisk. Challenges involve high costs and regulatory complexities. Opportunities lie in obesity treatment expansion and advanced drug delivery systems. European Glucagon-like Peptide-1 (GLP-1) Agonists Market Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034" has been added to offering. The Europe glucagon-like peptide-1 (GLP-1) agonists market is projected to witness significant growth, fueled primarily by an increased prevalence of type 2 diabetes and obesity. Originally valued at USD 7.09 billion in 2024, the market is estimated to expand at a compound annual growth rate (CAGR) of 17.30%, expecting a valuation of USD 14.34 billion by 2034. The competitive landscape features major pharmaceutical firms like Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, and others focused on innovative R&D, strategic collaborations, and drug formulation advancements. These companies aim to enhance market presence through mergers, acquisitions, and partnerships that promote access and compliance, ensuring sustained growth in the Europe's GLP-1 agonists market. The market's expansion is propelled by the increasing incidence of diabetes and obesity, augmented by sedentary lifestyles and poor dietary choices. GLP-1 agonists, as incretin-based therapies, are preferred for their efficacy in controlling blood sugar levels and facilitating weight loss, crucial aspects in managing diabetes and obesity. The growth trajectory is supported by rising healthcare expenditure, a burgeoning elderly demographic, advancements in drug delivery, and a robust regulatory framework favoring novel therapeutic adoption. Key Attributes: Report Attribute Details No. of Pages 300 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $7.09 Billion Forecasted Market Value (USD) by 2034 $14.34 Billion Compound Annual Growth Rate 7.3% Regions Covered Europe Market Drivers A surge in type 2 diabetes and obesity cases. Favorable government initiatives and reimbursement policies bolstering access to innovative treatments. Improved drug formulations like once-weekly injectables and oral options enhancing patient compliance. A growing trend towards combination therapies integrating GLP-1 agonists for optimized results. Market Challenges High costs of GLP-1 therapies affecting widespread accessibility. Potential side effects that could hinder patient adherence. Regulatory complexities delaying new therapy commercializations. Future Opportunities Expanding applications in obesity treatment beyond diabetes management. Innovative drug delivery system developments heightening market penetration. Strategic R&D investments for next-gen GLP-1 therapies with enhanced efficacy. Europe GLP-1 Agonists Market Trends The shift towards long-acting GLP-1 formulations like once-weekly injections elevating patient compliance. The increasing use of GLP-1 agonists in obesity management, supported by regulatory endorsements. Clinical validation of cardiovascular benefits driving GLP-1 adoption among patients at cardiovascular risk. Policymaker efforts in expanding healthcare coverage improving treatment accessibility. The development of multi-target GLP-1 therapies promises superior management of diabetes and weight issues. Strategic collaborations in biosimilar production broadening market access and affordability. Market Segmentation By Drugs: Key drugs include dulaglutide, exenatide, liraglutide, tirzepatide, lixisenatide, and semaglutide. By Application: The applications span type 2 diabetes mellitus and obesity treatment. By Route of Administration: Dominated by parenteral routes, the market is gradually seeing a rise in oral solution adoption. By End User: Primary users are hospitals, specialty clinics, academic research sites, with home care settings gaining traction. By Distribution Channel: Hospital pharmacies prevail, while retail and online pharmacies steadily gain ground. By Region: The United Kingdom, Germany, France, and Italy emerge as principal markets, bolstered by strong infrastructure and supportive policies. Companies Featured Eli Lilly and Company Sanofi Novo Nordisk A/S AstraZeneca plc For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment European Glucagon-like Peptide-1 (GLP-1) Agonists Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Bloomberg
an hour ago
- Bloomberg
Epstein-Barr Is More Dangerous Than You Think
Hi it's Karoline in Singapore, where one in four people will get cancer in their lifetime. A recent study found a common virus could be more powerful in causing cancers than previously thought. More on that in a moment, but first ... The Epstein-Barr virus is one of the most common human viruses, with more than 90% of people in the world being infected at some point of their lives. It's spread by saliva and causes mononucleosis, known as the 'kissing disease.' Though EBV generally causes mild flu-like symptoms, it has been linked to immune dysfunctions, lymphomas and nose and stomach cancers.
Washington Post
an hour ago
- Washington Post
Airplanes are loud and may damage your hearing. Here's what helps.
Even if you can ignore the sounds of crying babies and booming pilot announcements, airplanes can be loud. That's usually due to another constant noise that you may not notice when settling into a long flight: The roar of the engines. Despite advances in acoustic sound management, experts say this constant noise could be a source of discomfort and potentially even a risk to health and hearing. However, there is not much direct research on how airplane noise affects passengers.
